Reuters logo
BRIEF-Celgene updates 2017, long-term outlook
January 9, 2017 / 5:40 PM / 9 months ago

BRIEF-Celgene updates 2017, long-term outlook

Jan 9 (Reuters) - Celgene

* CEO says 2016 sales $11.2 billion

* Celgene sees 2017 adjusted EPS $7.10 to $7.75, revenue $13 billion to $13.4 billion

* Celgene sees 2017 Revlimid sales $8 billion to $8.3 billion

* Celgene sees 2020 sales greater than $21 billion

* Celgene says expects to file seeking approval for Ozanimod in multiple sclerosis by year end

* Celgene CEO says 4 of 14 products in development have multibillion-dollar potential

* Celgene says 2020 forecast largely based on growing existing products

* Celgene says “vast majority” of growth projections based on volume rather than price increases Source text for Eikon: Further company coverage: (Reporting By Bill Berkrot)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below